The ALK (anaplastic lymphoma kinase) in Lung Cancer Trial of Brigatinib in 1st Line (ALTA-1L) [14] was a randomized, open-label, controlled, phase 3 study evaluating the efficacy of brigatinib (experimental arm) versus crizotinib (control arm) on Progression-Free Survival (PFS). This evidence concerns the gene ALK and lung carcinoma.